Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1985 6
1986 19
1987 68
1988 30
1989 82
1990 56
1991 56
1992 48
1993 69
1994 66
1995 76
1996 58
1997 66
1998 62
1999 76
2000 54
2001 42
2002 48
2003 53
2004 62
2005 46
2006 51
2007 42
2008 41
2009 36
2010 34
2011 42
2012 43
2013 38
2014 21
2015 22
2016 29
2017 30
2018 37
2019 22
2020 16
2021 21
2022 16
2023 18
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

1,639 results

Results by year

Filters applied: . Clear all
Page 1
Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial.
Ewoldt TMJ, Abdulla A, Rietdijk WJR, Muller AE, de Winter BCM, Hunfeld NGM, Purmer IM, van Vliet P, Wils EJ, Haringman J, Draisma A, Rijpstra TA, Karakus A, Gommers D, Endeman H, Koch BCP. Ewoldt TMJ, et al. Intensive Care Med. 2022 Dec;48(12):1760-1771. doi: 10.1007/s00134-022-06921-9. Epub 2022 Nov 9. Intensive Care Med. 2022. PMID: 36350354 Free PMC article. Clinical Trial.
PURPOSE: Individualising drug dosing using model-informed precision dosing (MIPD) of beta-lactam antibiotics and ciprofloxacin has been proposed as an alternative to standard dosing to optimise antibiotic efficacy in critically ill patients. ...CONCLUSIONS: We could not sh …
PURPOSE: Individualising drug dosing using model-informed precision dosing (MIPD) of beta-lactam antibiotics and ciprofloxacin has be …
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial.
Chu L, Acosta AM, Aazami H, Dennis P, De Valle O, Ehmer D Jr, Hedrick JA, Ansley JF. Chu L, et al. JAMA Netw Open. 2022 Jul 1;5(7):e2221699. doi: 10.1001/jamanetworkopen.2022.21699. JAMA Netw Open. 2022. PMID: 35834251 Free PMC article. Clinical Trial.
IMPORTANCE: Ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution seems to be efficacious and safe in treating acute otitis externa (AOE) compared with ciprofloxacin, 0.3%, or fluocinolone acetonide, 0.025%, otic solution alone. OBJECTIVE: To evalu …
IMPORTANCE: Ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution seems to be efficacious and safe in treating acut …
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, Bevins CL, Bambrick ML, Seidner DL, Fazio VW. Shen B, et al. Inflamm Bowel Dis. 2001 Nov;7(4):301-5. doi: 10.1097/00054725-200111000-00004. Inflamm Bowel Dis. 2001. PMID: 11720319 Clinical Trial.
Sixteen patients were randomized to a 2-week course of ciprofloxacin 1,000 mg/d (n = 7) or metronidazole 20 mg/kg/d (n = 9). ...Ciprofloxacin should be considered as one of the first-line therapies for acute pouchitis....
Sixteen patients were randomized to a 2-week course of ciprofloxacin 1,000 mg/d (n = 7) or metronidazole 20 mg/kg/d (n = 9). ...Ci …
Ciprofloxacin.
Terp DK, Rybak MJ. Terp DK, et al. Drug Intell Clin Pharm. 1987 Jul-Aug;21(7-8):568-74. doi: 10.1177/1060028087021007-801. Drug Intell Clin Pharm. 1987. PMID: 3301247 Review.
Clinical trials using the oral preparation of ciprofloxacin have demonstrated its effectiveness in a wide variety of infections. ...In addition, the incidence of ciprofloxacin-related side effects throughout its clinical trials has been minimal. ...
Clinical trials using the oral preparation of ciprofloxacin have demonstrated its effectiveness in a wide variety of infections. ...I …
Pharmacokinetics and bioequivalence study of two ciprofloxacin hydrochloride tablets in healthy Chinese subjects under fasting and fed conditions: A randomized, open-label, two-formulation, two-sequence, two-period, single-dose crossover study.
Qin F, Wang GM, Huang JY, Wu JR, Song WJ, Deng J, Xiao Y, Wang JS, Zhu KW. Qin F, et al. Int J Clin Pharmacol Ther. 2021 Dec;59(12):804-816. doi: 10.5414/CP204032. Int J Clin Pharmacol Ther. 2021. PMID: 34503644 Clinical Trial.
OBJECTIVE: The study mainly aimed to determine the bioequivalence of two branded ciprofloxacin hydrochloride tablets (250 mg) under fasting and fed conditions. ...In each period of the study, the subjects were assigned to receive a single oral dose of 250 mg cipr …
OBJECTIVE: The study mainly aimed to determine the bioequivalence of two branded ciprofloxacin hydrochloride tablets (250 mg) …
Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding.
Sifuentes-Osornio J, Macías A, Amieva RI, Ramos A, Ruiz-Palacios GM. Sifuentes-Osornio J, et al. Am J Med. 1989 Nov 30;87(5A):202S-205S. doi: 10.1016/0002-9343(89)90059-4. Am J Med. 1989. PMID: 2686425 Clinical Trial.
Oral ciprofloxacin has been shown to be effective in the treatment of infections due to gram-positive cocci and gram-negative rods. ...The bacteriologic responses were eradication in 28 ciprofloxacin cases/22 ceftazidime cases; persistence, one/three; and indetermin …
Oral ciprofloxacin has been shown to be effective in the treatment of infections due to gram-positive cocci and gram-negative rods. . …
Worldwide clinical data on efficacy and safety of ciprofloxacin.
Schacht P, Arcieri G, Branolte J, Bruck H, Chyský V, Griffith E, Gruenwaldt G, Hullmann R, Konopka CA, O'Brien B, et al. Schacht P, et al. Infection. 1988;16 Suppl 1:S29-43. doi: 10.1007/BF01650504. Infection. 1988. PMID: 3286511 Review.
During the clinical trials 8,861 patients have been treated with ciprofloxacin worldwide. 3,822 of the therapeutic courses were valid for analysis of efficacy according to FDA standards. ...Thus the total incidence of side-effects for the treated patient population was 10. …
During the clinical trials 8,861 patients have been treated with ciprofloxacin worldwide. 3,822 of the therapeutic courses were valid …
On ciprofloxacin concentration in chronic rhinosinusitis.
Gameiro Dos Santos J, Figueirinhas R, Liberal JP, Almeida JC, Sousa J, Falcão A, Vicente C, Paço J, Sousa CA. Gameiro Dos Santos J, et al. Acta Otorrinolaringol Esp (Engl Ed). 2018 Jan-Feb;69(1):35-41. doi: 10.1016/j.otorri.2017.06.008. Epub 2017 Aug 30. Acta Otorrinolaringol Esp (Engl Ed). 2018. PMID: 28859993 Clinical Trial. English, Spanish.
The plasma and mucosal ciprofloxacin concentrations were assayed with high performance liquid chromatography (HPLC) with fluorescence detection (FD). RESULTS: The oral ciprofloxacin achieved better mucosal concentrations but had a significant plasmatic expression in …
The plasma and mucosal ciprofloxacin concentrations were assayed with high performance liquid chromatography (HPLC) with fluorescence …
Safety of oral ciprofloxacin. An update based on clinical trial results.
Schacht P, Arcieri G, Hullmann R. Schacht P, et al. Am J Med. 1989 Nov 30;87(5A):98S-102S. doi: 10.1016/0002-9343(89)90033-8. Am J Med. 1989. PMID: 2686432 Review.
The safety of ciprofloxacin was established on a data base (compiled through the end of 1988) of 9,473 well-documented treatment courses world-wide. ...The worldwide data from clinical trials with oral ciprofloxacin clearly demonstrate that the drug is relatively sa …
The safety of ciprofloxacin was established on a data base (compiled through the end of 1988) of 9,473 well-documented treatment cour …
1,639 results